By Budi Oetomo Narendra 
Medications are designed to treat diseases and relieve symptoms, but some can also produce unintended effects that put patients at risk. While side effects are common with many treatments, researchers have identified a particularly concerning possibility involving drugs used to control inflammation, with new findings from Norway suggesting that a widely used class of anti-inflammatory medications may inadvertently facilitate viral infection and dissemination throughout the body. This discovery challenges existing understandings of these powerful drugs and necessitates a re-evaluation of their risk-benefit profiles, particularly in the context of ongoing viral threats.
Scientists at the Norwegian University of Science and Technology (NTNU) have uncovered that a class of drugs known as Janus kinase (JAK) inhibitors, frequently prescribed for various autoimmune and inflammatory conditions, could inadvertently make it easier for several significant viruses to infect human cells and propagate. "We have found a surprising and potentially serious side effect of a class of anti-inflammatory drugs. They can help viruses spread more easily in the body," stated Denis Kainov, a professor at NTNU’s Department of Clinical and Molecular Medicine, highlighting the gravity of this unexpected interaction. This revelation introduces a new layer of complexity to the therapeutic landscape, prompting an urgent call for increased awareness and further investigation into optimal prescribing practices.
The Double-Edged Sword of Inflammation and Immune Modulation
Inflammation is a fundamental biological process, serving as the body’s immediate response to injury, infection, or irritation. While acute inflammation is crucial for healing and defense, chronic or dysregulated inflammation can lead to a host of debilitating conditions, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and severe forms of atopic dermatitis. For decades, scientists have sought effective ways to modulate this intricate process without compromising the body’s broader immune defenses. This quest led to the development of targeted therapies, among the most prominent being JAK inhibitors.
JAK inhibitors operate by blocking the activity of Janus kinase enzymes, which are critical components of the JAK-STAT signaling pathway. This pathway is pivotal in transmitting signals from outside the cell to the nucleus, regulating a vast array of cellular processes, including immune cell development, function, and the production of cytokines—small proteins that act as messengers between immune cells. By inhibiting JAK enzymes, these drugs effectively dampen inflammatory responses, offering significant relief to patients suffering from chronic inflammatory diseases. Drugs like tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), and filgotinib (Jyseleca) have revolutionized the treatment of conditions that were previously challenging to manage, significantly improving patients’ quality of life. The global market for JAK inhibitors has expanded considerably, with hundreds of thousands, if not millions, of patients worldwide relying on these medications. For instance, global sales for JAK inhibitors reached several billion dollars annually by the early 2020s, underscoring their widespread clinical adoption.
However, the very mechanism that makes JAK inhibitors effective—their ability to modulate the immune system—also carries inherent risks. Immune suppression is a known side effect of these drugs, leading to increased susceptibility to various infections, including bacterial, fungal, and opportunistic infections. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have issued "black box warnings" for JAK inhibitors, cautioning about the risk of serious infections, malignancy, and thrombotic events. Despite these known risks, the specific mechanism of facilitating viral spread had not been thoroughly elucidated until the recent NTNU study.
Unveiling the Viral Vulnerability: The NTNU Study
The groundbreaking research, published in NAR Molecular Medicine, meticulously investigated the interaction between JAK inhibitors and viral infections. The medications at the core of these findings are widely prescribed to control inflammation, but their systemic effects on the immune system appear to leave the body more susceptible to viral invasion and dissemination. Professor Kainov elaborated on the spectrum of viruses implicated: "Among the viruses that more easily affect the body with the help of these drugs are Rift Valley fever virus, influenza A, adenovirus and SARS-CoV-2, the virus that causes COVID-19." The inclusion of SARS-CoV-2 is particularly noteworthy, given the drug baricitinib’s emergency use authorization and subsequent approval for severe COVID-19 cases, where its anti-inflammatory properties were leveraged to mitigate the cytokine storm associated with critical illness. This paradox—a drug used to treat severe viral disease potentially aiding viral spread—underscores the complexity of host-pathogen interactions and drug pharmacology.
Erlend Ravlo, a PhD research fellow at NTNU and first author of the article, explained the underlying mechanism: "JAK inhibitors are often prescribed for autoimmune diseases and inflammatory conditions such as rheumatoid arthritis." While these medications are highly effective at reducing inflammation, their benefits come with a significant trade-off. By suppressing specific immune responses, they interfere with the very mechanisms designed to protect the body from viral infections. "In particular, the drugs suppress an important immune signaling pathway that helps protect healthy cells from viral attacks," Ravlo added. This pathway plays a central role in coordinating the body’s immediate and adaptive immune responses when viruses attempt to infect healthy tissue, activating genes responsible for antiviral defense.
The research team, including Aleksandr Ianevski, an NTNU researcher and co-author, found that JAK inhibitors, specifically mentioning baricitinib, could significantly reduce the activity of genes crucial for fighting viral infections. "These genes play a crucial role in the body’s response to viral infections," Ianevski emphasized. When JAK inhibitors disrupt this critical immune signaling system, they effectively dismantle an important layer of antiviral protection. Without the robust defensive response, viruses may encounter fewer obstacles, finding it easier to establish an infection within cells and subsequently spread to neighboring cells, tissues, and potentially throughout the body.
To arrive at these conclusions, the scientists employed a sophisticated array of advanced virology methods, coupled with comprehensive gene expression analysis and cutting-edge organoid technology. Their experiments were not limited to a single cell type but encompassed diverse human tissues, including cells derived from the lungs, eyes, and brain, along with miniature organ models grown in the laboratory. This multi-faceted approach allowed the team to examine precisely how the drugs affect antiviral defenses across various physiological contexts, providing robust evidence for their findings. The implication is clear: "Although JAK inhibitors are effective in the treatment of inflammation, this shows that they can pose a hidden risk for patients who have latent or active viral infections," Ravlo concluded, urging a cautious approach.
A Timeline of Discovery and Evolving Understanding
The journey of JAK inhibitors from laboratory discovery to widespread clinical use spans several decades. The Janus kinase family of enzymes was first identified in the late 1980s and early 1990s. Initial research focused on understanding their fundamental role in cytokine signaling. By the early 2000s, pharmaceutical companies began to develop molecules specifically designed to inhibit these enzymes, recognizing their potential as therapeutic targets for autoimmune diseases. Tofacitinib, the first JAK inhibitor, received FDA approval in 2012 for rheumatoid arthritis, marking a new era in the treatment of chronic inflammatory conditions. Subsequent years saw the approval of other JAK inhibitors for an expanding list of indications, including psoriatic arthritis, ulcerative colitis, atopic dermatitis, and even alopecia areata, demonstrating their broad utility.
The initial clinical trials and post-market surveillance for these drugs identified an increased risk of serious infections as a general class effect. This was largely attributed to the broad immune-suppressing nature of the drugs. However, the specific mechanism of facilitating viral spread as identified by the NTNU study adds a nuanced and potentially more insidious dimension to this risk. The connection to SARS-CoV-2 is particularly poignant. Baricitinib, for instance, gained significant attention during the COVID-19 pandemic. In November 2020, it received Emergency Use Authorization from the FDA for use in hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Its anti-inflammatory properties were considered beneficial in mitigating the hyper-inflammatory state, or "cytokine storm," observed in severe COVID-19 cases. The NTNU findings, therefore, present a critical re-evaluation point, suggesting that while the drug might calm an overactive immune response in the lungs, it could simultaneously, or at other stages of infection, inadvertently aid the virus in establishing and spreading its initial foothold.
This new research builds upon a growing body of knowledge regarding the complex interplay between inflammation, immune modulation, and viral pathogenesis. The previous understanding focused more on the general immunocompromised state. The NTNU study’s distinction lies in demonstrating a specific mechanism of viral entry and spread facilitation, rather than just a general weakening of the immune system against any infection.
Broader Implications for Patients, Prescribers, and Public Health
The ramifications of these findings are substantial and extend across multiple facets of healthcare and public health.
For Patients: Individuals currently taking JAK inhibitors for chronic inflammatory conditions should not abruptly discontinue their medication. Instead, the findings underscore the importance of open and thorough discussions with their healthcare providers. Patients need to be fully informed about the potential risks, especially concerning viral infections, and should report any symptoms of infection promptly. Personalized risk assessment, considering the patient’s overall health, vaccination status, and local epidemiological context (e.g., during flu season or viral outbreaks), becomes even more critical. Patient advocacy groups for autoimmune diseases would likely emphasize the importance of shared decision-making and continuous monitoring.
For Healthcare Professionals: The research necessitates a heightened level of caution in prescribing JAK inhibitors. Clinicians, particularly rheumatologists, dermatologists, and gastroenterologists, must carefully weigh the benefits of inflammation control against the potential for increased viral vulnerability. This is especially pertinent during periods of elevated viral transmission, such as seasonal influenza outbreaks or during pandemics. Researchers suggest that healthcare professionals should exercise caution when prescribing these medications during periods of increased viral transmission. This might involve more rigorous screening for latent viral infections, more proactive vaccination strategies, or even temporary cessation of the drug during acute viral illnesses, although such decisions require careful clinical judgment. Leading medical societies, such as the American College of Rheumatology or the European League Against Rheumatism, would likely issue updated advisories or guidelines to their members, urging them to integrate these new insights into their clinical practice.
For Pharmaceutical Companies and Regulatory Bodies: The findings will likely prompt pharmaceutical companies that develop and market JAK inhibitors to review their product labeling and conduct further post-marketing surveillance studies. While these companies are committed to patient safety and continuously monitor emerging research, this specific mechanism of viral spread facilitation may warrant additional warnings or recommendations. Regulatory bodies like the FDA and EMA will undoubtedly evaluate these findings in light of existing safety profiles and may consider issuing new guidelines or strengthening existing advisories concerning the use of JAK inhibitors, particularly during widespread viral outbreaks.
For Public Health: The study carries significant implications for public health strategies, especially in the context of pandemic preparedness and response. Understanding how widely used drugs can influence viral spread is crucial for modeling disease transmission, developing effective containment strategies, and prioritizing vaccination efforts. If a significant portion of the population on these drugs becomes more efficient viral spreaders, it could impact herd immunity thresholds and the overall trajectory of outbreaks.
Future Research and Optimizing Treatment Strategies
The NTNU researchers are not only highlighting a risk but also pointing towards pathways for future investigation. The same immune-suppressing properties that create potential risks for patients could, paradoxically, offer advantages in certain controlled laboratory settings. Under these conditions, the ability of JAK inhibitors to facilitate viral entry and spread might be harnessed by scientists to develop more effective vaccines or to evaluate potential antiviral medications. By making cells more permissive to viral infection, researchers could potentially accelerate studies on viral replication cycles and drug efficacy.
However, the primary focus remains on patient safety and optimizing therapeutic outcomes. "We recommend further studies to better understand how the drugs can be used optimally, especially during virus outbreaks or pandemics," stated Ianevski, underscoring the urgent need for more data. Future research could explore several avenues:
- Dose Optimization: Are there lower effective doses that minimize viral facilitation while still controlling inflammation?
- Drug Combinations: Can JAK inhibitors be safely combined with antivirals or immunomodulators that counteract their viral-spreading effect?
- Biomarkers: Can biomarkers be identified to predict which patients are at higher risk of viral complications when taking JAK inhibitors?
- Novel JAK Inhibitors: Can next-generation JAK inhibitors be designed to be more selective, perhaps targeting specific JAK isoforms that are less critical for antiviral defense?
- Real-world Data: Large-scale observational studies using real-world data would be invaluable to confirm these findings in diverse patient populations and epidemiological settings.
Professor Magnar Bjørås of the Department of Clinical and Molecular Medicine provided significant scientific expertise and secured most of the funding for this pivotal research. Additional financial support came from prestigious institutions including the Central Norway Regional Health Authority, the South-Eastern Norway Regional Health Authority, the Research Council of Norway, and the Swedish Research Council, reflecting the broad scientific interest and importance placed on this area of investigation.
In conclusion, the NTNU study represents a critical advancement in our understanding of how widely used anti-inflammatory drugs interact with the immune system and viral pathogens. It forces a careful re-evaluation of the risk-benefit balance of JAK inhibitors, particularly in an era frequently impacted by viral outbreaks and pandemics. While these drugs offer invaluable relief for millions suffering from chronic inflammatory diseases, this new knowledge mandates a more nuanced and cautious approach to their prescription and monitoring, ultimately aiming to ensure both effective disease management and the paramount safety of patients. The ongoing scientific endeavor will undoubtedly strive to refine treatment strategies, develop safer alternatives, and ensure that medical interventions continue to serve humanity’s best interests without unintended consequences.
